Evidence tracker Pharmacology Delirium prevention

Dexmedetomidine to prevent postoperative delirium

Does perioperative dexmedetomidine prevent delirium, and in whom? Compare dosing and timing, cardiac versus noncardiac surgery, and delirium outcomes alongside bradycardia and hypotension.

Indexed papers
19
matching, retractions excluded
Randomized trials
4
plus 2 meta-analyses
With AI summary
19
others show original abstract
Registered, not results
0
ongoing trials
Clinical assessment not completed. No bottom line, certainty grade, or curated effect sizes have been written for this topic. Below is a source-linked inventory of matching papers (up to 200 from our cache), not a systematic review. Read the original studies before drawing conclusions.

Published studies

Open in feed

Recent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.

Showing 4 of 19 · RCT

Recent evidence · past year

  1. RCT Drug Des Devel TherPublished 27 Oct 2026 Li Q et al.
    Effect of Preoperative Intranasal Dexmedetomidine on Postoperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting.
    AI summary of the abstract, unverified
    • Randomized, double-blind, placebo-controlled single-center trial of 70 patients undergoing on-pump CABG.
    • Patients received intranasal dexmedetomidine 1 μg/kg or saline on the night before surgery and again 30 minutes before induction.
    • At 24 hours, estimated marginal mean hs-cTnT was 170.29 vs 357.29 ng/L (P < 0.001) favoring dexmedetomidine; CK-MB was also lower.
    • Sleep quality scores were higher and postoperative delirium was lower (14.3% vs 37.1%; P = 0.029), but the authors call the findings preliminary.
    Original abstract (PubMed)

    PURPOSE: To evaluate the effects of preoperative intranasal dexmedetomidine on postoperative myocardial injury biomarkers in patients undergoing on-pump coronary artery bypass grafting (CABG). PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, 70 patients undergoing on-pump CABG were assigned to receive intranasal dexmedetomidine (1 μg/kg) or saline 30 min before bedtime on the night before surgery and again 30 min before anesthesia induction. The primary outcome was serum high-sensitivity cardiac troponin T (hs-cTnT) at 24 h after surgery. Secondary outcomes included perioperative cardiac biomarkers, preoperative sleep quality, postoperative delirium, and adverse events. RESULTS: For the prespecified primary outcome, hs-cTnT concentrations at 24 h after surgery were significantly lower in the dexmedetomidine group than in the control group (estimated marginal means, 170.29 vs 357.29 ng/L; P < 0.001). Postoperative creatine kinase-MB (CK-MB) concentrations were also lower in the dexmedetomidine group (all P < 0.05). N-terminal pro-B-type natriuretic peptide showed a significant group-by-time interaction (P = 0.030), although between-group differences at individual postoperative time points were not significant. The dexmedetomidine group had higher Leeds Sleep Evaluation Questionnaire scores (62 [60-64] vs 44 [41-50]; P < 0.001) and a lower incidence of postoperative delirium (14.3% vs 37.1%; P = 0.029). Adverse events, mechanical ventilation duration, and intensive care unit (ICU) length of stay did not differ significantly between groups. CONCLUSION: In this single-center trial, two-dose preoperative intranasal dexmedetomidine was associated with lower postoperative hs-cTnT and CK-MB concentrations, better subjective preoperative sleep quality, and a lower observed incidence of postoperative delirium. These findings are preliminary and require confirmation in larger, adequately powered multicenter randomized trials to determine whether the biomarker reductions translate into clinically meaningful cardiovascular benefits. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2500111431.

  2. RCT Drug Des Devel TherPublished 2 Oct 2026 Zhang SJ et al.
    Intraoperative Dexmedetomidine and Postoperative Delirium After Head and Neck Cancer Surgery with Free-Flap Reconstruction: A Secondary Analysis of a Randomized Placebo-Controlled Trial.
    AI summary of the abstract, unverified
    • This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
    • Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
    • Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
    • Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
    Original abstract (PubMed)

    BACKGROUND: Postoperative delirium is common after major head and neck cancer surgery. We investigated whether intraoperative dexmedetomidine infusion was associated with a lower incidence of postoperative delirium in patients undergoing head and neck cancer surgery requiring free-flap reconstruction. METHODS: This was a delirium-focused secondary analysis of a single-centre, randomized, double-blind, placebo-controlled trial. Adult patients with head and neck cancer scheduled for elective surgery requiring free-flap reconstruction under general anaesthesia were randomly assigned to receive intraoperative dexmedetomidine infusion at 0.3 μg kg-1h-1 until 1 h before the end of surgery; subjects in the placebo group were given comparable volumes of normal saline. The primary outcome was the incidence of delirium during the first 5 postoperative days, assessed once daily using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Confusion Assessment Method (3D-CAM). RESULTS: There was less delirium during the initial 5 postoperative days in patients assigned to dexmedetomidine (14.9%, 7 of 47 patients) than in those given placebo (34.7%, 17 of 49 patients). Dexmedetomidine was associated with lower odds of postoperative delirium after adjustment for age, preoperative Mini-Mental State Examination score, and operative time (adjusted odds ratio 0.31, 95% confidence interval 0.10-0.92; p = 0.036). Postoperative pain and early sleep outcomes were improved by dexmedetomidine. Haemodynamic adverse events and postoperative complications did not differ significantly between groups. CONCLUSION: In patients undergoing head and neck cancer surgery with free-flap reconstruction, intraoperative dexmedetomidine infusion was associated with a lower incidence of postoperative delirium during the first 5 postoperative days, without an apparent increase in perioperative adverse events. CLINICAL TRIAL REGISTRATION: ChiCTR2300067376.

  3. RCT Drug Des Devel TherPublished 13 Sep 2026 Chen Y et al.
    Effects of Intranasal Dexmedetomidine on the Night Before Surgery on Postoperative Delirium in Elderly Patients Undergoing Total Knee/Hip Arthroplasty. A Parallel-Arm, Randomized Controlled, Non-Inferiority Trial.
    AI summary of the abstract, unverified
    • Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
    • Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
    • Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
    • Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.
    Original abstract (PubMed)

    IMPORTANCE: It is crucial to identify preoperative treatment methods that can safely and effectively reduce the incidence of postoperative delirium. OBJECTIVE: To evaluate whether preoperative intranasal dexmedetomidine administration for preventing postoperative delirium is non-inferior to intravenous dexmedetomidine infusion on the operative day before induction for elderly patients undergoing elective knee/hip arthroplasty. DESIGN: This randomized clinical trial was performed at a tertiary hospital in China between January 10, 2025 to August 30, 2025. The follow-up for the last subject was completed on September 6, 2025. SETTING: This was a single center trial. PARTICIPANTS: After qualification screening, 535 patients scheduled for unilateral total knee arthroplasty and total hip arthroplasty under general anesthesia were invited to participate in the study. Ultimately, 316 patients were randomly assigned to the experimental group and the control group. INTERVENTIONS: Patients were randomized to receive intranasal dexmedetomidine (the night before surgery)+intravenous normal saline (before induction) or intranasal normal saline (the night before surgery)+intravenous dexmedetomidine (before induction). MAIN OUTCOMES AND MEASURES: The primary outcome was incidence of postoperative delirium within 3 days after surgery assessed by the Confusion Assessment Method. RESULTS: In the intention-to-treat analysis, the incidence of postoperative delirium within 3 days was 9.5% in experimental group and 7.6% in control group. The rate difference was 0.02 (95% CI: -0.04 to 0.08), meeting the pre-specified non-inferiority criterion (P < 0.001). Patients in experimental group showed significantly improved sleep quality on the night before surgery and lower preoperative anxiety and pain scores. Furthermore, the incidence of adverse events was significantly lower in experimental group. CONCLUSIONS AND RELEVANCE: For elderly patients undergoing major joint arthroplasty, intranasal dexmedetomidine administered the night before surgery is non-inferior to pre-induction intravenous infusion for preventing postoperative delirium. The intranasal route offers additional benefits, including improved preoperative sleep, reduced anxiety, and superior hemodynamic stability.

  4. RCT Drug Des Devel TherPublished 17 Aug 2026 Liu Y et al.
    Effect of Intranasal Dexmedetomidine on the Night Before Surgery for Postoperative Delirium in Older Patients Undergoing Total Hip or Knee Arthroplasty: A Randomized Clinical Trial.
    AI summary of the abstract, unverified
    • Double-blind, placebo-controlled single-center randomized trial of 232 patients aged 60 or older, ASA 1 to 3, undergoing total hip or knee arthroplasty in China.
    • Intranasal dexmedetomidine 100 μg versus normal saline given at 21:00 on the night before surgery.
    • Delirium within 3 postoperative days occurred in 10.3% versus 20.7% (relative risk 0.50; 95% CI 0.26-0.95; P=0.030) in the intention-to-treat analysis.
    • The authors report improved sleep quality and reduced anxiety and pain, with no severe adverse events or nasal mucosal injury, and suggest sleep improvement may partly explain the delirium reduction.
    Original abstract (PubMed)

    IMPORTANCE: Postoperative delirium is a common and serious neurocognitive complication in elderly arthroplasty patients, with preoperative poor sleep as a key risk factor. Effective preoperative prevention strategies remain an urgent clinical need. OBJECTIVE: To assess preoperative intranasal dexmedetomidine for preventing postoperative delirium in older adults undergoing hip or knee arthroplasty. DESIGN: This trial was conducted at a single tertiary academic hospital in China from January 10, 2025 to June 10, 2025, with follow-up assessments performed from admission to 7 days after surgery. SETTING: This was a single-center, double-blind, placebo-controlled randomized trial. PARTICIPANTS: 232 elderly patients aged 60 years or older, with American Society of Anesthesiologists (ASA) status 1 to 3, scheduled for total hip or knee arthroplasty under general anesthesia were enrolled and randomized 1:1 after eligibility screening. INTERVENTIONS: Intranasal dexmedetomidine(100 μg total dose) or normal saline, administered at 21:00 on the night before surgery. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of postoperative delirium within 3 postoperative days, evaluated by the Confusion Assessment Method. Secondary outcomes included postoperative delirium incidence within 7 days, duration, severity, subtype, perioperative sleep quality, pain, anxiety, quality of recovery, time to ambulation, and adverse events. RESULTS: In the intention-to-treat analysis, the postoperative delirium incidence within 3 days was 10.3% in the dexmedetomidine group and 20.7% in the placebo group [relative risk=0.50; 95% confidence interval (CI)=0.26-0.95; P=0.030]. Intranasal dexmedetomidine could improve sleep quality and reduce preoperative and postoperative anxiety and pain. No severe adverse events or nasal mucosal injuries were observed in either group. CONCLUSION: Intranasal dexmedetomidine on the night before surgery could reduce the incidence of postoperative delirium and improve perioperative sleep quality in older patients undergoing joint arthroplasty. Sleep improvement may partly explain this association, suggesting a potential supportive strategy for delirium prevention. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2500095414.

Earlier evidence / dates not confirmed

Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.

  1. No matching papers in this section with the selected filters.

Ongoing registrations

From ClinicalTrials.gov

Registrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.

No registered ongoing trials found.